Skip to content
Brand AI

Deciphera Pharmaceuticals

Request correction

Corporate brand

Unclaimed

Commercial-stage biopharmaceutical company developing kinase inhibitors to treat cancer.

Last updated September 11, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

Deciphera Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Waltham, MA, with research facilities in Lawrence, KS. It was founded in 2003 by Daniel L. Flynn, Ph.D. The company develops kinase inhibitors using its proprietary switch-control kinase inhibitor platform, with a pipeline of wholly-owned, orally administered drug candidates. As of June 11, 2024, Deciphera is a member of ONO Pharma.

History

Deciphera was founded in 2003 by Daniel L. Flynn, Ph.D. As of June 11, 2024, Deciphera is a member of ONO Pharma.

Recent events

  • Reported

    FDA approves Qinlock for advanced GIST[6]

    The FDA approved Deciphera Pharmaceuticals’ ripretinib (Qinlock) for fourth-line treatment of advanced gastrointestinal stromal tumors in adults previously treated with three or more kinase inhibitor therapies, including imatinib.

Read more

Sources6 sources

  1. 1Deciphera - One Mission, Inspired by Patients: Defeat Cancer.deciphera.com
  2. 2About | Decipheradeciphera.com
  3. 3Management | Decipheradeciphera.com
  4. 4Discovery Platform | Decipheradeciphera.com
  5. 5Deciphera Pharmaceuticals (United States)wikidata.org
  6. 6FDA批准Qinlock用于晚期胃肠道间质瘤ajmc.com

Cite this profile: Cite the canonical profile. /brand-wiki/deciphera-pharmaceuticals-united-states · Editorial policy · How profiles are compiled